BioSpace News Archive

Driven by pandemic realities and clinical demand for portable and intelligent point-of-care ultrasound, GE Healthcare unveiled Venue Fit™, a streamlined and compact POCUS system, alongside an industry-first AI offering for cardiac imaging on the Venue™ and Venue Go™.

Biom Therapeutics, a clinical stage biotech company, announced today it has received orphan drug designation status for BIO017—which is designed to treat Angelman syndrome—from the U.S. FDA’s Office of Orphan Product Development

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced the Denver Business Journal has recognized Zynex as the sixth largest Biotechnology/Bioscience public company

AscellaHealth, a national specialty pharmacy benefit manager (SPBM) serving commercial, Medicare and Medicaid segments, is collaborating with Group & Pension Administrators (GPA), the largest independently owned third-party administrator (TPA) in the Southwest, to present a webinar entitled “A TPA-Client Approach to Specialty Medical Cost Containment Strategy for Infusion Therapy Medications,” April 22, 1:30 p.m. (EDT)

Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced financial results for the full year 2020 and provided corporate updates.

He will be speaking on the use of psychedelics in treating obesity and eating disorders.

The agreement is subject to the completion of a definitive agreement between both parties.

The Partnership to Fight Chronic Disease (PFCD) today released, “Quantifying Impact of Accelerated Approval Drugs on Medicaid Spending: De Minimus Impact, Maximum Attention,” an economic analysis examining the impact of the Food and Drug Administration’s accelerated approval pathway on Medicaid spending.

Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a manufacturing agreement expansion with AstraZeneca to include drug product manufacturing.

exocad GmbH, an Align Technology, Inc. company, announced that DentalCAD 3.0 Galway, with new additional improvements to reduce design time is currently being rolled out to end users by exocad distributors.